文献速递免疫规划传染病防控与疫情报告

疫苗对印度尼西亚高致病性禽流感H5N1的效力:系统综述与Meta分析

Vaccine efficacy against Indonesian Highly Pathogenic Avian Influenza H5N1: systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2017-08-02

该系统综述与Meta分析检索7个数据库,纳入13篇文章的65项研究和46种疫苗配方,评估商业疫苗对印度尼西亚高致病性禽流感H5N1的免疫原性与效力。结果显示疫苗种子与流行株同一分支的匹配可能比血凝抑制抗体滴度更能预测效力,Meta分析提示高异质性(I2≥75%)及LPAI配方对当前流行株无效,作者认为需持续匹配疫苗种子与新兴H5N1分支并开展跨物种研究确认效力。

要点

  • 疫苗种子与攻击病毒属同一分支的匹配可能是比同源血凝抑制抗体滴度更好的效力预测指标。
  • Meta分析显示异质性高(I2≥75%),LPAI配方对当前流行株无效。
  • 早期接种可能增加死亡风险(组4),一株印尼疫苗对新优势分支在鸡中提供一致保护但在鸭中不然。

核心结论

  • 印度尼西亚商业疫苗的效力随H5N1演变为新分支而变化,应持续匹配疫苗种子与新兴H5N1。
  • 鉴于新印尼优势H5N1分支的特征,需进一步研究确认跨物种效力。

研究设计与样本

  • 系统综述与Meta分析,检索7个数据库,纳入13篇文章的65项研究和46种疫苗配方。
  • 按OIE效力方案分组(组1)及其变体(组2、3、4)。
  • 评估免疫原性及攻击后2天呼吸道和泄殖腔排毒预防效力及随访期末死亡。

主要发现

  • 疫苗种子与攻击病毒同一分支匹配可能是比当前基于疫苗同源HI抗体滴度的估计更好的效力替代指标,尤其针对当前第四阶分支病毒(组1和2)。
  • Prime-boosting在不同鸡品种中有效(组3),早期接种可能增加死亡风险(组4)。
  • 一株印尼疫苗针对新优势分支测试,在鸡中提供一致保护但在鸭中不然。
  • Meta分析显示高不一致性(I2≥75%)及LPAI配方对当前流行株无效。
  • 不一致效力的潜在来源包括种子同源疫苗的配方和接种物种。

局限性

  • Meta分析显示高不一致性(I2≥75%)。
  • 需进一步研究确认跨物种效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Indonesia has implemented multiple strategies to control Highly Pathogenic Avian Influenza H5N1 (HPAI/H5N1), including the licensure and use of multiple vaccine formulations. The continuous drift of Indonesian HPAI/H5N1 viruses and emergence of a new clade in 2012 that became dominant in 2016, demands the assessment of commercial vaccine formulations against Indonesian field viruses. Seven databases were explored to identify relevant literature reporting performance of commercial vaccines against Indonesian HPAI/H5N1 viruses. After methodological assessment, data were collated and analyzed to report immunogenicity and vaccine efficacy (VE) to prevent respiratory and cloacal viral shedding 2-day post challenge, and death at the end of the follow-up period. Meta-analyses were performed to assess VE consistency of alternative formulations and to explore sources of heterogeneity in VE. In total, 65 studies and 46 vaccine formulations from 13 articles were grouped per OIE's VE protocols (group 1) and variations of it (groups 2,3,4). We found that concurrence of vaccine-seed and challenge-viruses in a clade designation might be a better proxy of VE than current estimates based on vaccine-homologous HI antibody titers, particularly against current fourth order clade viruses (groups 1&2). Prime-boosting was efficacious across different chicken breeds (group 3), and early vaccination may increase the risk of death (group 4). One Indonesian vaccine was tested against the new dominant clade, conferring consistent protection in chickens but not in ducks. Meta-analyses revealed high inconsistency (I2≥75%) and inefficacy of LPAI formulations against current field viruses, while potential sources of inconsistent VE were formulation of seed-homologous vaccines and the species vaccinated. We conclude that the VE of commercial vaccines in Indonesia changes as Indonesian HPAI/H5N1 evolve into new clades, which should warrant continuous matching between vaccine-seeds and emerging HPAI/H5N1. Furthermore, given the characteristics of the new Indonesian dominant HPAI/H5N1 clade, further studies to confirm VE across species are warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Villanueva-Cabezas JP, Coppo MJC, Durr PA, et al. Vaccine efficacy against Indonesian Highly Pathogenic Avian Influenza H5N1: systematic review and meta-analysis. Vaccine. 2017. PMID: 28780119. doi:10.1016/j.vaccine.2017.07.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。